Marco Onofrj

Overview

Best Publications

• Peripheral cytokines profile in Parkinson's disease

  M. Reale;C. Iarlori;A. Thomas;D. Gambi

  599
  Citations

• EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up

  Laura Bonanni;Astrid Thomas;Pietro Tiraboschi;Bernardo Perfetti

  426
  Citations

• A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patch versus capsule

  Bengt Winblad;Jeffrey Cummings;Niels Andreasen;George Grossberg

  380
  Citations

• Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.

  Rupam Borgohain;J. Szasz;P. Stanzione;C. Meshram

  309
  Citations

• Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease.

  Lucilla Parnetti;Davide Chiasserini;Emanuele Persichetti;Paolo Eusebi

  265
  Citations

• Duration of amantadine benefit on dyskinesia of severe Parkinson’s disease

  A Thomas;D Iacono;A L Luciano;K Armellino

  263
  Citations

• What electrophysiology tells us about Alzheimer's disease: a window into the synchronization and connectivity of brain neurons.

  Claudio Babiloni;Katarzyna Blinowska;Laura Bonanni;Andrej Cichocki

  262
  Citations

• Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial

  Robert A Hauser;Marc Cantillon;Marc Cantillon;Emmanuelle Pourcher;Federico Micheli

  237
  Citations

• Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease.

  Alessio Di Fonzo;Alessio Di Fonzo;Cristina Tassorelli;Michele De Mari;Hsin F Chien

  220
  Citations

• Pathological gambling in Parkinson disease is reduced by amantadine

  Astrid Thomas;Laura Bonanni;Francesco Gambi;Angelo Di Iorio

  210
  Citations

• Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias†‡

  Lucilla Parnetti;Davide Chiasserini;Gianni Bellomo;David Giannandrea

  198
  Citations

• Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel

  Claudio Babiloni;Xianghong Arakaki;Hamed Azami;Karim Bennys

  186
  Citations

• Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study.

  Giovanni Martinotti;Gianna Sepede;Francesco Gambi;Giuseppe Di Iorio

  181
  Citations

• Proteomics characterization of extracellular vesicles sorted by flow cytometry reveals a disease-specific molecular cross-talk from cerebrospinal fluid and tears in multiple sclerosis.

  Damiana Pieragostino;Paola Lanuti;Ilaria Cicalini;Maria Concetta Cufaro

  176
  Citations

• Incidence of RBD and hallucination in patients affected by Parkinson's disease: 8-year follow-up.

  M. Onofrj;A. Thomas;G. D'Andreamatteo;D. Iacono

  174
  Citations

• Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism

  M. Onofrj;A.L. Luciano;A. Thomas;D. Iacono

  172
  Citations

• Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER.

  K. Ray Chaudhuri;Pablo Martinez-Martin;Angelo Antonini;Richard G. Brown

  168
  Citations

• Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.

  Werner Poewe;Erik Wolters;Murat Emre;Marco Onofrj

  165
  Citations

• LRP10 genetic variants in familial Parkinson's disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study

  Marialuisa Quadri;Wim Mandemakers;Martyna M. Grochowska;Roy Masius

  160
  Citations

• Early DEtection of wEaring off in Parkinson disease: the DEEP study.

  F Stocchi;A Antonini;P Barone;M Tinazzi

  159
  Citations

• A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients†‡§

  Fabrizio Stocchi;Rupam Borgohain;Marco Onofrj;Anthony H.V. Schapira

  148
  Citations

• Visual evoked potentials in parkinsonism and dopamine blockade reveal a stimulus-dependent dopamine function in humans.

  M Onofrj;M F Ghilardi;M Basciani;D Gambi

  148
  Citations

• Botulinum toxin treatment of lateral axial dystonia in Parkinsonism.

  Laura Bonanni;Astrid Thomas;Sara Varanese;Vincenzo Scorrano

  145
  Citations

• Quantitative electroencephalogram utility in predicting conversion of mild cognitive impairment to dementia with Lewy bodies

  Laura Bonanni;Bernardo Perfetti;Stefania Bifolchetti;John Paul Taylor

  138
  Citations

• Improvement of motor function in early Parkinson disease by safinamide

  F. Stocchi;G. Arnold;M. Onofrj;H. Kwiecinski

  129
  Citations